Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
NCT ID: NCT06926842
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
221 participants
INTERVENTIONAL
2025-04-22
2026-08-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
NCT06662539
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
NCT06132841
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06595238
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
NCT06851858
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
NCT02863419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment A: Petrelintide Dose 1
Randomized participants will receive weekly subcutaneous injections of petrelintide Dose 1.
Petrelintide
Petrelintide will be taken by participants once weekly subcutaneously.
Treatment B: Petrelintide Placebo Dose 1
Randomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide.
Placebo
Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
Treatment C: Petrelintide Dose 2
Randomized participants will receive weekly subcutaneous injections of petrelintide Dose 2.
Petrelintide
Petrelintide will be taken by participants once weekly subcutaneously.
Treatment D: Petrelintide Placebo Dose 2
Randomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide.
Placebo
Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
Treatment E: Petrelintide Dose 3
Randomized participants will receive weekly subcutaneous injections of petrelintide Dose 3.
Petrelintide
Petrelintide will be taken by participants once weekly subcutaneously.
Treatment F: Petrelintide Placebo Dose 3
Randomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide.
Placebo
Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Petrelintide
Petrelintide will be taken by participants once weekly subcutaneously.
Placebo
Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with type 2 diabetes ≥180 days prior to the day of screening.
* Treated with metformin with or without sodium-glucose cotransporter 2 inhibitors. Treatment should be stable (same drug\[s\], dose, and dosing frequency) for at least 90 days prior to screening.
Exclusion Criteria
* Receipt of any other glucose-lowering drug than those listed in the inclusion criterion within 90 days prior to screening.
* A self-reported change in body weight \>5% within 90 days prior to screening, irrespective of medical records.
* Treatment with any medication (prescribed or over-the-counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 90 days prior to screening.
* Previous or planned (during the trial period) obesity treatment with surgery or a body weight loss device. However, liposuction or surgical removal of fat depots more than 1 year prior to screening or device-based interventions (e.g., sleeve, banding, or similar) that have been removed more than 6 months prior to screening, are allowed.
* Obesity due to endocrine disorders or genetic syndromes.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parexel
INDUSTRY
Zealand Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cullman Clinical Trials - Family Medicine
Cullman, Alabama, United States
AZ Endocrine Institute
Chandler, Arizona, United States
Elite Clinical Studies, LLC
Phoenix, Arizona, United States
M3 Wake Research, Tucson Neuroscience Research, LLC
Tucson, Arizona, United States
Medical Investigation Inc
Little Rock, Arkansas, United States
Velocity Clinical Research
Huntington Park, California, United States
Velocity Clinical Research, North Hollywood
North Hollywood, California, United States
Exalt Clinical Research
San Diego, California, United States
Diablo Clinical Research Inc.
Walnut Creek, California, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Emerson Clinical Research
Washington D.C., District of Columbia, United States
Innovative Research of West Florida
Clearwater, Florida, United States
East Coast Institute for Research, LLC
Jacksonville, Florida, United States
Solutions Through Advanced Research, Inc
Jacksonville, Florida, United States
M3 Wake Research - Lake City
Lake City, Florida, United States
West Orange Endocrinology P.A
Ocoee, Florida, United States
Palm Beach Research Center
West Palm Beach, Florida, United States
M3 Wake Research - Atlanta
Atlanta, Georgia, United States
East Coast Institute for Research - Canton
Canton, Georgia, United States
Privia Medical Group Georgia, LLC
Savannah, Georgia, United States
Great Lakes Clinical Trials
Chicago, Illinois, United States
Iowa Diabetes & Endocrinology Research Center
West Des Moines, Iowa, United States
Heartland Research Associates, LLC
Wichita, Kansas, United States
DelRicht Research - New Orleans
New Orleans, Louisiana, United States
AAMRC
Flint, Michigan, United States
International Diabetes Center
Minneapolis, Minnesota, United States
Velocity Clinical Research, Gulfport
Gulfport, Mississippi, United States
AMR Kansas City
Kansas City, Missouri, United States
Mercury Street Medical Group, PLLC
Butte, Montana, United States
M3 Wake Research - Las Vegas, NV
Las Vegas, Nevada, United States
Palm Research Center, Inc.
Las Vegas, Nevada, United States
Javara Inc
Charlotte, North Carolina, United States
PharmQuest Life Sciences, LLC
Greensboro, North Carolina, United States
M3 Wake Research
Raleigh, North Carolina, United States
Velocity Clinical Research, Cincinnati, Mt. Auburn
Cincinnati, Ohio, United States
Centricity Research
Columbus, Ohio, United States
Lynn Institute of Norman
Norman, Oklahoma, United States
M3 Wake Research - Charleston
Charleston, South Carolina, United States
M3 Wake Research/ClinSearch, LLC
Chattanooga, Tennessee, United States
Elligo Clinical Research, Inc.
Austin, Texas, United States
The University of Texas Southwestern Medical Center
Dallas, Texas, United States
Juno Research LLC
Houston, Texas, United States
Tekton Research, LLC
Irving, Texas, United States
Tekton Research, LLC
McKinney, Texas, United States
Texas Health Care, PLLC
San Marcos, Texas, United States
Consano Clinical Research
Shavano Park, Texas, United States
Texas Health Care
Stephenville, Texas, United States
Manaasas Clinical Research Center
Manassas, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZP8396-24115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.